MaxCyte, Inc.

NASDAQ:MXCT

Medical - Devices

Healthcare
$1.25 +3.98%

+$0.05 today

Market cap
$129.06M
Beta
1.67
P/E (TTM)
-3.2
EPS (TTM)
-$0.37
52W Low $0.64High $2.37

Volume 0.97M

Average 0.95M

MXCT Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

MaxCyte, Inc.NASDAQ: MXCT

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation outflow shrinks to $0

Q1 FY2026 stock-based compensation was $0, compared with $3.04M a year earlier. Trailing-twelve-month stock-based compensation was $706K.

Context

  • Stock-based compensation amounted to 27.9% of revenue in FY2025, up 27.9 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $176.5K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$9.21M— YoY
LTMMar 2026
$706K-76.8% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
9.21M USD
Year-over-year change
—
4-year CAGR
+3.7%

Stock-Based Compensation vs competitors

How MXCT compares with its peers on the latest reported figures

  • MXCT's LTM Mar 2026 stock-based compensation of $706K is the 10th largest of the 11 companies compared; the peer median is $5.01M.
  • Its year-over-year change of -76.8% is the 10th highest of 11, against a peer median of -7.1%.
  • Stock-based compensation amounts to 2.2% of revenue for MXCT, versus a peer median of 25.8%.
MXCT Competitors Peer median
Stock-Based Compensation for MXCT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OWLTOwlet, Inc.LTM Mar 2026$11.18M +38.7%-10.1%10.4%
TLSITriSalus Life Sciences, Inc.LTM Mar 2026$9.98M +67.1%+191.7%22.2%
CATXPerspective Therapeutics, Inc.LTM Mar 2026$9.42M +38.0%+88.2%1524.4%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$7.48M -39.0%-34.0%21.6%
PROFProfound Medical Corp.LTM Mar 2026$5.55M +98.0%+9.0%29.4%
AVRAnteris Technologies Global Corp.LTM Mar 2026$4.48M -15.1%+38.4%241.9%
NNOXNano-X Imaging Ltd.LTM Dec 2025$4.19M -42.3%-39.2%32.2%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$2.9M -7.5%-5.6%98.2%
LNSRLENSAR, Inc.LTM Mar 2026$2.49M -6.7%-22.0%4.3%
MXCTMaxCyte, Inc.LTM Mar 2026$706K -76.8%—2.2%
PREPrenetics Global LimitedLTM Mar 2026$141K -98.0%—0.1%
Peer median (excluding MXCT) $5.01M-7.1%-5.6%25.8%

Competitors are the stored peer set for MXCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(19.08M)(23.57M)(37.92M)(41.06M)(44.63M)
Depreciation & Amortization1.42M2.7M4.57M4.32M5.14M
Deferred Income Tax00000
Stock-Based Compensation7.96M013.98M09.21M
Change in Working Capital(1.64M)(3.21M)3.82M(751K)(6.12M)
Accounts Receivables(1.71M)(6.69M)7.14M1.23M1.15M
Inventory(1.41M)(3.49M)(4.53M)1.36M575K
Accounts Payables2.09M(149.7K)3.25M(1.88M)(3.72M)
Other Working Capital(624.7K)7.12M(2.04M)(1.46M)(4.13M)
Other Non-Cash Items664.6K9.3M(6.13M)9.88M1.99M
Operating Cash Flow(10.68M)(14.78M)(21.69M)(27.61M)(34.41M)
Capital Expenditures(3.83M)(18.48M)(3.7M)(1.65M)(1.77M)
Acquisitions (Net)0000(1.77M)
Purchases of Investments(268.68M)(290.94M)(255.1M)(150.86M)(126.29M)
Sales of Investments77.5M284.6M313.77M159.44M155.76M
Other Investing Activities4.6K09K00
Investing Cash Flow(195.01M)(24.82M)54.98M6.93M25.94M
Debt Repayment(4.99M)0000
Common Stock Issued236.08M2.89M269K2.06M656K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.63M01.87M00
Financing Cash Flow234.72M2.89M2.14M2.06M656K
Effect of Forex Changes00000
Net Change in Cash29.03M(36.72M)35.44M(18.62M)(7.82M)
Free Cash Flow(14.51M)(33.26M)(25.39M)(29.26M)(36.18M)

MaxCyte, Inc.

NASDAQ:MXCT

Intrinsic Alpha fair value

Locked

Current Price

$1.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.